# US 2025/0327142 A1 · Methods of collecting and analyzing dust samples for surveillance of viral diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0327142 A1
- Document ID: US20250327142A1
- Status: Published application
- Kind: A1
- Application number: 18/290,623
- Filed: 2022-04-12
- Published: 2025-10-23
- Earliest claimed: 2021-07-22
- Assignees: Ohio State Innovation Foundation; University of Notre Dame du Lac
- Applicants: Ohio State Innovation Foundation; University of Notre Dame Du Lac
- Inventors: Karen DANNEMILLER; Natalie HULL; Kyle BIBBY; Seth FAITH; Nick NASTASI; Nicole RENNINGER
- Web page: https://patentgrep.com/patent/US20250327142A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described herein are methods for the detection of a virus (e.g., SARS-CoV-2) RNA in dust, which can be used for continued environmental surveillance of the viral disease. Targeted monitoring of dust in high-concern buildings can complement broader population-level monitoring approaches. Additionally, a method for detection of a viral RNA in a dust sample is disclosed herein.

## Claims

### Claim 1

A method for detection of a viral nucleic acid in a dust sample, comprising
a) extracting the viral nucleic acid from the dust sample;
b) determining a level of inhibition in the viral nucleic acid extracted from the dust sample;
c) diluting the viral nucleic acid extracted from the dust sample if the level of inhibition is increased in comparison to a control; and
d) quantifying an amount of the diluted viral nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein step a) comprises phenol-based lysis.

### Claim 3 (depends on 1)

The method of claim 1, wherein step a) comprises using a concentration of beta-mercaptoethanol about 10 times greater than a recommended concentration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amount of the diluted viral nucleic acid is quantified by a polymerase chain reaction (PCR) assay.

### Claim 5 (depends on 4)

The method of claim 4, wherein the PCR assay is a quantitative reverse transcription PCR (RT-qPCR) assay.

### Claim 6 (depends on 4)

The method of claim 4, wherein the PCR assay is a digital PCR assay.

### Claim 7 (depends on 6)

The method of claim 6, wherein the digital PCR assay is a chip-based digital PCR (dPCR) or droplet digital PCR (ddPCR) assay.

### Claim 8 (depends on 1)

The method of claim 1, further comprising sequencing the viral nucleic acid extracted from the dust sample.

### Claim 9 (depends on 1)

The method of claim 1, wherein the viral nucleic acid is a viral RNA or a viral DNA.

### Claim 10 (depends on 9)

The method of claim 9, wherein the viral RNA is an RNA of an airborne virus.

### Claim 11 (depends on 10)

The method of claim 10, wherein the RNA of the airborne virus is a SARS-CoV-2 RNA, an influenza RNA, or a respiratory syncytial virus (RSV) RNA.

### Claim 12 (depends on 1)

The method of claim 1, further comprising comparing the amount of the viral nucleic acid contained in the dust sample to a threshold value.

### Claim 13 (depends on 12)

The method of claim 12, wherein the threshold value is between about 50 copies per milligram (mg) dust and about 1000 copies per mg dust.

### Claim 14 (depends on 12)

The method of claim 12, wherein the threshold value is about 300 copies per mg dust.

### Claim 15

A method for environmental surveillance, comprising:
collecting a dust sample from an area inside an enclosed structure;
extracting viral nucleic acid from the dust sample;
quantifying an amount of the extracted viral nucleic acid contained in the dust sample; and
determining whether a viral disease is present inside the enclosed structure based on the amount of the extracted viral nucleic acid contained in the dust sample.

### Claim 16 (depends on 15)

The method of claim 15, further comprising generating a report comprising the amount of the extracted viral nucleic acid contained in the dust sample.

### Claim 17 (depends on 15)

The method of claim 15, further comprising comparing the amount of the extracted viral nucleic acid contained in the dust sample to a threshold value, wherein presence of the viral disease inside the enclosed structure is determined based on the comparison.

### Claim 18 (depends on 17)

The method of claim 17, wherein the viral disease is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and wherein the threshold value is between about 50 copies per milligram (mg) dust and about 1000 copies per mg dust.

### Claim 19 (depends on 18)

The method of claim 18, wherein the threshold value is about 300 copies per mg dust.

### Claim 20 (depends on 17)

The method of claim 17, further comprising recommending an action item from a risk management plan based on the comparison.

### Claim 21 (depends on 20)

The method of claim 20, wherein the action item is to test individuals for the viral disease.

### Claim 22 (depends on 20)

The method of claim 20, wherein the action item is to sequence viral nucleic acid extracted from the dust sample to detect variants.

### Claim 23 (depends on 15)

The method of claim 15, further comprising sequencing viral nucleic acid extracted from the dust sample to detect variants.

### Claim 24 (depends on 15)

The method of claim 15, further comprising correlating the amount of the extracted viral nucleic acid contained in the dust sample to an approximate number of infected individuals using the enclosed structure.

### Claim 25 (depends on 15)

The method of claim 15, further comprising sieving the dust sample prior to extracting viral nucleic acid from the dust sample.

### Claim 26 (depends on 15)

The method of claim 15, wherein the dust sample is a bulk dust sample.

### Claim 27 (depends on 15)

The method of claim 15, wherein the dust sample is a surface swab sample or an air sample.

### Claim 28 (depends on 15)

The method of claim 15, wherein the amount of the extracted viral nucleic acid from the dust sample is quantified by a polymerase chain reaction (PCR) assay.

### Claim 29 (depends on 28)

The method of claim 28, wherein the PCR assay is a quantitative reverse transcription PCR (RT-qPCR) assay.

### Claim 30 (depends on 28)

The method of claim 28, wherein the PCR assay is a digital PCR assay.

### Claim 31 (depends on 30)

The method of claim 30, wherein the digital PCR assay is a chip-based digital PCR (dPCR) or droplet digital PCR (ddPCR) assay.

### Claim 32 (depends on 15)

The method of claim 15, wherein the viral disease is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

### Claim 33 (depends on 15)

The method of claim 15, wherein the viral nucleic acid is a viral RNA or a viral DNA.
